Proactive Investors - Run By Investors For Investors

Cellmid appoints experienced retail executive to board as it targets US and Asia

Dennis Eck has also been engaged in developing the retail strategies of US groups as well as Coles Myer.
Picture of woman with evolis caption
Eck should provide valuable input regarding product and distribution strategies for évolis

Cellmid Limited (ASX:CDY) has appointed Dennis Eck to the board as non-executive director.

A professional investor, Eck has 40 years’ senior management experience in the retail sector, leading the strategic direction of companies such as American Stores, Vons and ULTA in the US.

He has also been engaged in a similar capacity with Coles Myer in Australia.

Relevant experience in cosmetics and hair care

Eck’s retail experience spans from fashion through to groceries and includes cosmetics and hair salons.

As a senior strategist, Mr Eck has helped reshape the operations of several retail businesses, delivering outstanding shareholder returns.

Cellmid chairman David King said: “We are delighted to welcome Dennis to the board and look forward to his continued valuable input regarding our product and distribution strategy for évolis.”

Important in entering US and Asian markets

With substantial US and Asian market opportunities for évolis®, Eck’s experience should be beneficial.

In December 2017, Eck made a strategic investment in Cellmid through a private placement by acquiring 2.7 million fully paid ordinary shares.

Consequently, his interests are closely aligned with the shareholders he represents. 

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

Surgery
February 21 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Antigens
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
1550762209_shutterstock_291998651.jpg
February 22 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use